Baxter closes $153m hemostat, sealant asset buy from Mallinckrodt

Baxter (NYSE:BAX) said today that it closed the $153 million acquisition of hemostat and sealant assets from Mallinckrodt Pharmaceuticals (NYSE:MNK).

Baxter announced in January its plan to acquire the stand-alone recombinant thrombin Recothrom and Preveleak surgical sealant for vascular reconstruction.

“We are excited to add both Recothrom and Preveleak to our portfolio of hemostats and sealants to offer surgeons additional options that address different situations when intraoperative bleeding can occur,” advanced surgery president Wil Boren said in prepared remarks. “Our top priority right now is working with customers and distributors to ensure a smooth transition.”

Baxter said it expects its new purchases to add “modestly” to its adjusted earnings per share this year and increasingly after that. The deal includes possible milestone payments for an unspecified amount, the Deerfield, Ill.-based company said.

Recothrom is a stand-alone recombinant thrombin-based product with indications as an aid to hemostasis to control oozing blood and minor bleeding from capillaries and small venules when control of bleeding by standard surgical techniques is ineffective or impractical. Preveleak is designed to seal suture holes during surgical repair of the circulatory system and to reinforce sutured connections between blood vessels. Sales of both products totaled approximately $56 million during the 12 months preceding Sept. 29, 2017.

The post Baxter closes $153m hemostat, sealant asset buy from Mallinckrodt appeared first on MassDevice.

Baxter subsidiary sues B. Braun over blood filtration system


BaxterBaxter (NYSE:BAX) and its subsidiary Gambro filed a patent infringement lawsuit against B. Braun last week, claiming that the German medical device maker’s Omni blood purification system infringes on seven of the patents covering Baxter’s Prismaflex system.

The devices are used to treat patients who have acute kidney injuries and need help filtering out the waste products that accumulate in the blood.

Both the Omni system and the Prismaflex system deliver continuous renal replacement therapy – a form of hemodialysis where the patient’s blood is removed and processed through a hemofilter.

Baxter alleges that B. Braun’s product infringes on a number of the features covered by patents owned by Baxter. In the company’s initial compliant, it points to features like cartridge housings attached to the blood passage and the filtrate line that extend outwardly from the system, which Baxter says infringes upon U.S. Patent No. 6,887,214.

B. Braun’s Omni blood purification system has only been on the U.S. market since November. But Baxter argued in its complaint that B. Braun’s infringement on the seven named patents will result in loss of market share for the Prismaflex system.

“Such losses cannot be adequately compensated by money damages,” the company wrote.

Baxter asked the U.S. Court for the Eastern District of Pennsylvania to stop B. Braun from infringing upon Baxter’s patents and to cover the company’s costs and legal fees.

Here’s what the FDA is doing about IV fluid shortages following hurricanes Maria, Irma


FDANine weeks after hurricanes Maria and Irma brought devastation to Puerto Rico, FDA commissioner Dr. Scott Gottlieb says hospitals across the U.S. are reporting shortages of IV fluids – medical products that are often sourced from Puerto Rico.

Hospitals are specifically noting that 0.9% injection bags of saline, used to inject drugs intravenously, are of short supply. Gottlieb said in a prepared statement that despite the agency’s best efforts, the damage to Puerto Rico’s infrastructure has “greatly exacerbated this supply issue.”

Get the full story at our sister site, Drug Delivery Business News.